Abeona Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $290.5M
- Price
- $5.08
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.40%
- Volume
- 738.3K
About
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Quick stats
Shares outstanding57.2M
Computed float47.4M
Float / shares82.8%
Cash runway (months)21.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000318306
AI Summary
AI-generated1/40
minorneutralother
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics granted restricted stock inducement awards covering up to 7,200 shares to two newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards were approved by the Compensation Committee on September 30, 2026, and vest one-third annually over three years subject to continued employment.
The grant size is immaterial relative to a commercial-stage biopharma; this is boilerplate HR disclosure, not a strategic or financial update.